Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise

Like
Comment
Favorite

Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise

MT Newswires Live01:29

Xencor (XNCR) said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology, or ESMO, Congress in October.

The company said expansion cohorts are evaluating intravenous doses to support selection of a recommended dose for a planned phase 3 study in advanced clear cell renal cell carcinoma, which is expected to begin in 2027.

Shares of Xencor were up 8.6% in Friday afternoon trading.

Price: 16.24, Change: +1.28, Percent Change: +8.56

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2652821492?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-18 01:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652821492","market":"us","top_or_hot":-1,"title":"Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> Xencor (XNCR) said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology, or ESMO, Congress in October.</p><p>The company said expansion cohorts are evaluating intravenous doses to support selection of a recommended dose for a planned phase 3 study in advanced clear cell renal cell carcinoma, which is expected to begin in 2027.</p><p>Shares of Xencor were up 8.6% in Friday afternoon trading.</p><p>Price: 16.24, Change: +1.28, Percent Change: +8.56</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-18 01:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Xencor (XNCR) said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology, or ESMO, Congress in October.</p><p>The company said expansion cohorts are evaluating intravenous doses to support selection of a recommended dose for a planned phase 3 study in advanced clear cell renal cell carcinoma, which is expected to begin in 2027.</p><p>Shares of Xencor were up 8.6% in Friday afternoon trading.</p><p>Price: 16.24, Change: +1.28, Percent Change: +8.56</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XNCR","symbol_name":"Xencor Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2652821492","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652821492","pubTimestamp":1784309354,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Xencor  said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology, or ESMO, Congress in October.The company said expansion cohorts are evaluating intravenous doses to support selection of a recommended dose for a planned phase 3 study in advanced clear cell renal cell carcinoma, which is expected to begin in 2027.Shares of Xencor were up 8.6% in Friday afternoon trading.Price: 16.24, Change: +1.28, Percent Change: +8.56","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XNCR":"Xencor Inc","BK4139":"生物科技"},"translate_title":"Xencor 的癌症药物研究被选中在 ESMO 上进行口头报告；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XNCR":1.5},"content_text":"Xencor (XNCR) said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology, or ESMO, Congress in October.The company said expansion cohorts are evaluating intravenous doses to support selection of a recommended dose for a planned phase 3 study in advanced clear cell renal cell carcinoma, which is expected to begin in 2027.Shares of Xencor were up 8.6% in Friday afternoon trading.Price: 16.24, Change: +1.28, Percent Change: +8.56","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}